
|Articles|April 27, 2003
Bladder cancer test offers results in 30 minutes
Cytogen Corp. and Matritech, Inc., offer the NMP22 BladderChek point-of-caretest for bladder cancer, which is now approved for detecting the disease.The product had been previously approved for monitoring patients who hadalready been diagnosed with bladder cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
Optimizing care for men with overactive bladder, with Keith Xavier, MD
4
The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH
5






